NASDAQ:NKTR Nektar Therapeutics (NKTR) Stock Price, News & Analysis → Radical change coming — do this NOW to protect yourself (From Weiss Ratings) (Ad) Free NKTR Stock Alerts $1.19 +0.02 (+1.71%) (As of 02:09 PM ET) Add Compare Share Share Today's Range$1.13▼$1.1950-Day Range$1.17▼$1.8352-Week Range$0.41▼$1.93Volume838,183 shsAverage Volume1.97 million shsMarket Capitalization$218.98 millionP/E RatioN/ADividend YieldN/APrice Target$3.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Nektar Therapeutics alerts: Email Address Nektar Therapeutics MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside195.4% Upside$3.50 Price TargetShort InterestHealthy1.53% of Float Sold ShortDividend StrengthN/ASustainability-1.77Upright™ Environmental ScoreNews Sentiment0.72Based on 7 Articles This WeekInsider TradingSelling Shares$165,089 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.84) to ($0.72) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.71 out of 5 starsMedical Sector234th out of 913 stocksPharmaceutical Preparations Industry101st out of 429 stocks 3.0 Analyst's Opinion Consensus RatingNektar Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, 3 hold ratings, and 1 sell rating.Amount of Analyst CoverageNektar Therapeutics has received no research coverage in the past 90 days.Read more about Nektar Therapeutics' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.53% of the float of Nektar Therapeutics has been sold short.Short Interest Ratio / Days to CoverNektar Therapeutics has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Nektar Therapeutics has recently increased by 3.40%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldNektar Therapeutics does not currently pay a dividend.Dividend GrowthNektar Therapeutics does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreNektar Therapeutics has received a 60.23% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Topoisomerase 1 (TOP1) inhibitors", "Clinical research services", and "Peripheral opioid receptor antagonists" products. See details.Environmental SustainabilityThe Environmental Impact score for Nektar Therapeutics is -1.77. Previous Next 2.1 News and Social Media Coverage News SentimentNektar Therapeutics has a news sentiment score of 0.72. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.92 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Nektar Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 2 people have searched for NKTR on MarketBeat in the last 30 days. This is a decrease of -78% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Nektar Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $165,089.00 in company stock.Percentage Held by InsidersOnly 3.71% of the stock of Nektar Therapeutics is held by insiders.Percentage Held by Institutions75.88% of the stock of Nektar Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Nektar Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Nektar Therapeutics are expected to grow in the coming year, from ($0.84) to ($0.72) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Nektar Therapeutics is -1.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Nektar Therapeutics is -1.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNektar Therapeutics has a P/B Ratio of 1.72. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Nektar Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsRadical change coming — do this NOW to protect yourselfI recently uncovered a way the government could use the next crisis as a pretext to gain more control … and radically change life in America as we know it today. And a Draconian set of technologies that could impose a new kind of financial surveillance in America. Click here to learn more. About Nektar Therapeutics Stock (NASDAQ:NKTR)Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.Read More NKTR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NKTR Stock News HeadlinesJune 15 at 9:33 AM | insidertrades.comNektar Therapeutics (NASDAQ:NKTR) Director Sells $23,400.00 in StockMay 21, 2024 | insidertrades.comJonathan Zalevsky Sells 7,355 Shares of Nektar Therapeutics (NASDAQ:NKTR) StockMay 21, 2024 | insidertrades.comInsider Selling: Nektar Therapeutics (NASDAQ:NKTR) CEO Sells 16,650 Shares of StockJune 16 at 6:56 AM | americanbankingnews.comRobert Chess Sells 19,500 Shares of Nektar Therapeutics (NASDAQ:NKTR) StockJune 12, 2024 | prnewswire.comNektar Therapeutics Presents First Preclinical Data on NKTR-0165, a TNFR2 Agonist Antibody Being Developed for the Treatment of Inflammatory Diseases, at EULAR 2024June 12, 2024 | americanbankingnews.comNektar Therapeutics (NASDAQ:NKTR) Stock Crosses Above 200-Day Moving Average of $0.94May 30, 2024 | prnewswire.comNektar Management to Present at Upcoming Investor ConferencesMay 24, 2024 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Nektar Therapeutics (NKTR) and BioNTech SE (BNTX)May 11, 2024 | uk.finance.yahoo.comQ1 2024 Nektar Therapeutics Earnings CallMay 10, 2024 | finance.yahoo.comNektar Therapeutics (NKTR) First Quarter 2024 Earnings OverviewMay 10, 2024 | finance.yahoo.comNektar Therapeutics (NASDAQ:NKTR) Q1 2024 Earnings Call TranscriptMay 10, 2024 | msn.comNKTR Stock Earnings: Nektar Therapeutics Meets EPS, Beats Revenue for Q1 2024May 9, 2024 | markets.businessinsider.comNektar Therapeutics Q1 Loss Drops In Line With EstimatesMay 9, 2024 | washingtonpost.comNektar: Q1 Earnings SnapshotMay 9, 2024 | prnewswire.comNektar Therapeutics Reports First Quarter 2024 Financial ResultsMay 8, 2024 | markets.businessinsider.comHere's what Wall Street expects from Nektar Therapeutics's earningsMay 2, 2024 | prnewswire.comNektar to Announce Financial Results for the First Quarter 2024 on Thursday, May 9, 2024, After Close of U.S.-Based Financial MarketsApril 24, 2024 | globenewswire.comBiolojic Design Announces that Nektar Therapeutics Has Exercised Its License Option to Develop an AI-Designed Agonistic Antibody Targeting TNFR2 for the Treatment of Autoimmune DiseasesApril 20, 2024 | finance.yahoo.comNatural Killer (NK) Cell Therapy Pipeline Research Report 2024: Comprehensive Insights About 100+ Companies and 185+ Pipeline DrugsApril 20, 2024 | investing.comNektar regains Nasdaq compliance with bid priceApril 10, 2024 | seekingalpha.comNektar Therapeutics Sees Something In The Data And Puts Its Drug To The TestMarch 29, 2024 | yahoo.com“A fascinating listen that sometimes sounds like a missing 10cc album plus a little Be Box Deluxe”: Nektar’s Recycled 5CD setMarch 22, 2024 | prnewswire.comNektar Management to Present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual ConferenceMarch 5, 2024 | finance.yahoo.comNektar Therapeutics (NASDAQ:NKTR) Q4 2023 Earnings Call TranscriptMarch 5, 2024 | finance.yahoo.comQ4 2023 Nektar Therapeutics Earnings CallSee More Headlines Receive NKTR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nektar Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today6/17/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals Current SymbolNASDAQ:NKTR CUSIP64026810 CIK906709 Webwww.nektar.com Phone(415) 482-5300Fax415-339-5300Employees137Year Founded1990Price Target and Rating Average Stock Price Target$3.50 High Stock Price Target$6.00 Low Stock Price Target$1.00 Potential Upside/Downside+199.1%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($0.92) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-276,060,000.00 Net Margins-195.02% Pretax Margin-195.21% Return on Equity-107.31% Return on Assets-38.08% Debt Debt-to-Equity RatioN/A Current Ratio6.10 Quick Ratio5.79 Sales & Book Value Annual Sales$90.12 million Price / Sales2.39 Cash FlowN/A Price / Cash FlowN/A Book Value$0.69 per share Price / Book1.70Miscellaneous Outstanding Shares184,020,000Free Float177,193,000Market Cap$215.30 million OptionableOptionable Beta0.71 Social Links Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. Howard W. Robin (Age 71)CEO, President & Director Comp: $1.83MMr. Mark A. Wilson (Age 52)Senior VP, Chief Legal Officer & Secretary Comp: $749.99kDr. Jonathan Zalevsky Ph.D. (Age 49)Chief Research & Development Officer Comp: $1.25MMs. Sandra A. Gardiner (Age 58)Interim Chief Financial Officer Vivian WuDirector of Investor Relations & Corporate AffairsMr. Robert BacciSenior Vice President of Human Resources & Facilities OperationsMs. Jennifer RuddockChief Business OfficerDr. Mary Tagliaferri L.Ac. (Age 58)M.D., Chief Medical Officer More ExecutivesKey CompetitorsOmerosNASDAQ:OMERADC TherapeuticsNYSE:ADCTAtea PharmaceuticalsNASDAQ:AVIRSeres TherapeuticsNASDAQ:MCRBAssembly BiosciencesNASDAQ:ASMBView All CompetitorsInsiders & InstitutionsRobert ChessSold 19,500 sharesTotal: $23,400.00 ($1.20/share)Lynx1 Capital Management LPBought 139,644 shares on 5/30/2024Ownership: 1.127%Howard W RobinSold 16,650 sharesTotal: $29,137.50 ($1.75/share)Jonathan ZalevskySold 7,355 sharesTotal: $12,871.25 ($1.75/share)Jacobs Levy Equity Management Inc.Sold 1,492,979 shares on 5/16/2024Ownership: 1.041%View All Insider TransactionsView All Institutional Transactions NKTR Stock Analysis - Frequently Asked Questions Should I buy or sell Nektar Therapeutics stock right now? 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Nektar Therapeutics in the last twelve months. There are currently 1 sell rating, 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" NKTR shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NKTR, but not buy additional shares or sell existing shares. View NKTR analyst ratings or view top-rated stocks. What is Nektar Therapeutics' stock price target for 2024? 5 Wall Street analysts have issued twelve-month target prices for Nektar Therapeutics' shares. Their NKTR share price targets range from $1.00 to $6.00. On average, they expect the company's share price to reach $3.50 in the next year. This suggests a possible upside of 195.4% from the stock's current price. View analysts price targets for NKTR or view top-rated stocks among Wall Street analysts. How have NKTR shares performed in 2024? Nektar Therapeutics' stock was trading at $0.5650 on January 1st, 2024. Since then, NKTR shares have increased by 109.7% and is now trading at $1.1850. View the best growth stocks for 2024 here. When is Nektar Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024. View our NKTR earnings forecast. How were Nektar Therapeutics' earnings last quarter? Nektar Therapeutics (NASDAQ:NKTR) announced its quarterly earnings data on Thursday, May, 9th. The biopharmaceutical company reported ($0.18) EPS for the quarter, topping analysts' consensus estimates of ($0.21) by $0.03. The biopharmaceutical company had revenue of $21.64 million for the quarter, compared to the consensus estimate of $14.91 million. Nektar Therapeutics had a negative net margin of 195.02% and a negative trailing twelve-month return on equity of 107.31%. During the same quarter in the prior year, the business posted ($0.25) earnings per share. What is Howard W. Robin's approval rating as Nektar Therapeutics' CEO? 46 employees have rated Nektar Therapeutics Chief Executive Officer Howard W. Robin on Glassdoor.com. Howard W. Robin has an approval rating of 81% among the company's employees. What other stocks do shareholders of Nektar Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Nektar Therapeutics investors own include Micron Technology (MU), NVIDIA (NVDA), Alibaba Group (BABA), Gilead Sciences (GILD), Intel (INTC), Pfizer (PFE), Advanced Micro Devices (AMD), Bristol-Myers Squibb (BMY), Netflix (NFLX) and Incyte (INCY). Who are Nektar Therapeutics' major shareholders? Nektar Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (6.56%), Acadian Asset Management LLC (4.12%), Monaco Asset Management SAM (3.18%), Lynx1 Capital Management LP (1.13%), GSA Capital Partners LLP (1.08%) and Jacobs Levy Equity Management Inc. (1.04%). Insiders that own company stock include Deep Track Capital, Lp, Gil M Labrucherie, Howard W Robin, Howard W Robin, Jillian B Thomsen, John Northcott, Jonathan Zalevsky, Karin Eastham, Mark Andrew Wilson, Myriam Curet, Robert Chess and Roy A Whitfield. View institutional ownership trends. How do I buy shares of Nektar Therapeutics? Shares of NKTR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:NKTR) was last updated on 6/17/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredJeff Bezos & 48 Members of Congress Are Buying ONE Sector…Why are Warren Buffett, Jeff Bezos, Michael Bloomberg, “The Walmart Family”, Bill Gates, and 48 members of Con...InvestorPlace | SponsoredThe Scary Fed Idea To Turn Your Dollars Into a Digital Power GrabCash is becoming a relic of the past… Soon, Biden and the Federal Reserve plan to replace the dollar with t...Oasis Gold | SponsoredBiden out June 13; replacement chosen?On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in...Paradigm Press | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredHe Is Giving Away BitcoinAnd my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a v...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nektar Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share Nektar Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.